Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claude Monneret

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Anti-Cancer Drugs|March 14, 2007
Histone deacetylase inhibitors for epigenetic therapy of cancerClaude Monneret
Comptes Rendus Biologies|November 12, 2017
What is an endocrine disruptor?Claude Monneret
European Journal of Medicinal Chemistry|January 12, 2005
Histone deacetylase inhibitorsClaude Monneret
Bioorganic & Medicinal Chemistry|April 26, 2003
Prodrug Mono Therapy: synthesis and biological evaluation of an etoposide glucuronide-prodrugFrédéric Schmidt, Claude Monneret
Topics in Current Chemistry|April 23, 2013
Doxorubicin conjugates for selective delivery to tumorsJean-Claude Florent, Claude Monneret
Bioorganic & Medicinal Chemistry Letters|November 1, 2003
Synthesis and antiproliferative activity of retroetoposidePhilippe Meresse, Prokopios Magiatis, Emmanuel Bertounesque, et al.
Organic & Biomolecular Chemistry|October 31, 2003
A new paclitaxel prodrug for use in ADEPT strategyEmmanuel Bouvier, Sylvie Thirot, Frédéric Schmidt, et al.
Bioorganic & Medicinal Chemistry|February 26, 2004
First enzymatically activated Taxotere prodrugs designed for ADEPT and PMTEmmanuel Bouvier, Sylvie Thirot, Frédéric Schmidt, et al.
Current Medicinal Chemistry|September 24, 2004
Etoposide: discovery and medicinal chemistryPhilippe Meresse, Elsa Dechaux, Claude Monneret, et al.
Organic & Biomolecular Chemistry|July 7, 2005
Synthesis and biological evaluation of vinylogous combretastatin A-4 derivativesJulia Kaffy, Renée Pontikis, Jean-Claude Florent, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Anti-Cancer Drugs|March 14, 2007
Histone deacetylase inhibitors for epigenetic therapy of cancerClaude Monneret
Comptes Rendus Biologies|November 12, 2017
What is an endocrine disruptor?Claude Monneret
European Journal of Medicinal Chemistry|January 12, 2005
Histone deacetylase inhibitorsClaude Monneret
Bioorganic & Medicinal Chemistry|April 26, 2003
Prodrug Mono Therapy: synthesis and biological evaluation of an etoposide glucuronide-prodrugFrédéric Schmidt, Claude Monneret
Topics in Current Chemistry|April 23, 2013
Doxorubicin conjugates for selective delivery to tumorsJean-Claude Florent, Claude Monneret
Bioorganic & Medicinal Chemistry Letters|November 1, 2003
Synthesis and antiproliferative activity of retroetoposidePhilippe Meresse, Prokopios Magiatis, Emmanuel Bertounesque, et al.
Organic & Biomolecular Chemistry|October 31, 2003
A new paclitaxel prodrug for use in ADEPT strategyEmmanuel Bouvier, Sylvie Thirot, Frédéric Schmidt, et al.
Bioorganic & Medicinal Chemistry|February 26, 2004
First enzymatically activated Taxotere prodrugs designed for ADEPT and PMTEmmanuel Bouvier, Sylvie Thirot, Frédéric Schmidt, et al.
Current Medicinal Chemistry|September 24, 2004
Etoposide: discovery and medicinal chemistryPhilippe Meresse, Elsa Dechaux, Claude Monneret, et al.
Organic & Biomolecular Chemistry|July 7, 2005
Synthesis and biological evaluation of vinylogous combretastatin A-4 derivativesJulia Kaffy, Renée Pontikis, Jean-Claude Florent, et al.
Pageof 4